An interventional study of Sham Device and Auricular transcutaneous vagus nerve stimulation in Chronic Dizziness and Persistent Postural Perceptual Dizziness, sponsored by Mayo Clinic. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Dizziness with a site in United States — 16 open to participants now, 19 under way, 1 of them phase 3. Dizziness · United States.
Among the 78 studies in Dizziness with a site in United States, this one is the 23rd largest by planned enrollment of the 68 interventional ones that give a count, is one of 3 that started in 2026, is one of 51 with no phase, reaches primary completion later than 9 of the 18 other live ones, and was the 77th registered.
228 studies on the registry are indexed under Dizziness; 57 are open to participants now.
Browse Dizziness studies →16 of the 78 studies in Dizziness with a site in United States are open now. Recruiting first, the newest first:
Boston Children's Hospital · Sites in United States
Ages 13–25
Northwestern University · Sites in United States
Ages 18+
Mountain Home Research & Education Corporation · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 22–90
University of California, Los Angeles · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 28 Dizziness studies recruiting now, 11 (39%) set no upper age limit and 11 (39%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 7
First in 1996; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 42 across 172 interventional studies indexed under Dizziness.
Median enrollment 35 across the 68 interventional studies, 133 across the 10 observational. Of the 50 that completed or were terminated, 26 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 78 have an industry lead sponsor. The 10 most frequent:
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
Mayo Clinic has 2 studies filed under Dizziness — fewer than ten, so there is no comparison to draw.
11 of the studies in Dizziness with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06859788Phase 3Sound Pharmaceuticals, IncorporatedSPI-1005 for the Treatment of Meniere's Disease (Open Label) | 2026-12 |
| NCT07099222University of ArizonaEfficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks | 2026-12-31 |
| NCT05674786Johns Hopkins UniversityVestibular Implantation to Treat Adult-Onset Bilateral Vestibular Hypofunction | 2026-12-31 |
| NCT06062368Johns Hopkins UniversityReducing Vertigo Associated With MRI Machines | 2027-01-01 |
| NCT07420803Mayo ClinicA Study Of Auricular Transcutaneous Vagus Nerve Stimulation In Chronic Dizziness | 2027-03 |
Add all 11 to your calendar (.ics) → With an account.
Among the 78 studies in Dizziness with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to measure the change in dizziness, as measured by change in Dizziness Handicap Inventory (DHI) score, following a 4-week treatment period with auricular transcutaneous vagus nerve stimulation (aTVNS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The vagus nerve stimulation group will perform two sessions per day (morning and evening), each lasting approximately 30 minutes, for a total of 1 hour of auricular transcutaneous vagus nerve stimulation. This arm will continue using the active treatment for 8 weeks.
Other: Auricular transcutaneous vagus nerve stimulation
The sham control group will will perform two sessions per day (morning and evening), each lasting approximately 30 minutes, for a total of 1 hour of daily stimulation using the sham device. After 4 weeks, the sham control group will begin active auricular transcutaneous vagus nerve stimulation for 4 weeks.
Other: Sham Device · Other: Auricular transcutaneous vagus nerve stimulation
The sham control uses the same stimulation devices as the active group, but with modified electrodes that do not emit electrical current. Instead, they produce a mechanical vibration or clicking sensation that mimics the feeling of stimulation without delivering current to the skin.
The Parasym AVNT is a noninvasive, transcutaneous auricular vagus nerve stimulator (tVNS) designed to deliver low-level electrical stimulation to the auricular branch of the vagus nerve through the skin of the outer ear. The stimulator produces mild, pulsed electrical currents typically ranging from 0.1 to 5.0 milliampere (mA) at frequencies between 20-30 Hz and pulse widths of approximately 200-300 μs. The stimulation intensity is adjusted individually to produce a light tingling sensation without discomfort or visible muscle contraction.
Change in Dizziness Handicap Inventory (DHI) score
The Dizziness Handicap Inventory (DHI) is a 25-item questionnaire assesses physical, emotional, and functional aspects of dizziness. Each of the 25 questions has three answers: "Always" (4 points), "Sometimes" (2 points), or "No" (0 points). Scores are summed for a total from 0 (no disability) to 100 (maximum disability).
Time frame: Baseline, 4 weeks
Change in Anxiety (HADS-A)
The Hospital Anxiety and Depression (HAD) is a self-reported 14 item questionnaire asking participants to reflect on their mood in the past week. . Each item is rated on a 4-point scale, for a total score ranging from 0-21 for each subscale. A higher score indicates higher distress. Clinically meaningful change is defined as a ≥2-3-point reduction.
Time frame: Baseline, 4 weeks and 8 weeks
Change in Postural Sway
Postural sway will be measured using Computerized Dynamic Posturography. A ≥10-15% reduction will be considered a meaningful improvement.
Time frame: Baseline, 4 weeks and 8 weeks
Weekly averages of dizzy-day frequency
Frequency of dizzy days will be tracked via patient treatment diary
Time frame: Through end of study, approximately 8 weeks
Plan to share: No
Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.
Of 84 non-industry interventional studies with no phase under Dizziness, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 42. This study's planned 12 months is below that.
Counting every sponsor, half of 92 studies reached it within 19 months; a quarter within 8 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.